Research programme: anticancer small molecules - Acerand Therapeutics
Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Acerand Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 28 Aug 2024 Early research in Solid tumours in China, USA (unspecified route) before August 2024 (Acerand Therapeutics pipeline, August 2024)